Loading…
Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study
Type 2 diabetes mellitus (T2DM) is a chronic progressive disease that requires treatment intensification with antihyperglycemic agents due to progressive deterioration of β-cell function. A large observational study of 45,868 patients with T2DM across 27 countries (EDGE) assessed the effectiveness a...
Saved in:
| Published in: | Vascular health and risk management 2015-01, Vol.11 (default), p.149-155 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c614t-8b7b128086eba764b8cd5b811f56d36598033214296c2314ef8f394c1d1957823 |
|---|---|
| cites | |
| container_end_page | 155 |
| container_issue | default |
| container_start_page | 149 |
| container_title | Vascular health and risk management |
| container_volume | 11 |
| creator | Saab, Charles Al-Saber, Feryal A Haddad, Jihad Jallo, Mahir Khalil Steitieh, Habib Bader, Giovanni Ibrahim, Mohamed |
| description | Type 2 diabetes mellitus (T2DM) is a chronic progressive disease that requires treatment intensification with antihyperglycemic agents due to progressive deterioration of β-cell function. A large observational study of 45,868 patients with T2DM across 27 countries (EDGE) assessed the effectiveness and safety of vildagliptin as add-on to other oral antidiabetic drugs (OADs) versus other comparator OAD combinations. Here, we present results from the Middle East countries (Bahrain, Jordan, Kuwait, Lebanon, Oman, Palestine, and the United Arab Emirates).
Patients inadequately controlled with OAD monotherapy were eligible after the add-on treatment was chosen by the physician based on clinical judgment and patient need. Patients were assigned to either vildagliptin or comparator OADs (sulfonylureas, thiazolidinediones, glinides, α-glucosidase inhibitors, or metformin, except incretin-based therapies) based on the add-on therapy. The primary endpoint was the proportion of patients achieving a glycated hemoglobin (HbA1c) reduction of >0.3% without peripheral edema, hypoglycemia, discontinuation due to a gastrointestinal event, or weight gain≥5%. One of the secondary endpoints was the proportion of patients achieving HbA1c |
| doi_str_mv | 10.2147/VHRM.S73703 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_0c30047b44e34b30a0008e0a64254b8d</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A449108758</galeid><doaj_id>oai_doaj_org_article_0c30047b44e34b30a0008e0a64254b8d</doaj_id><sourcerecordid>A449108758</sourcerecordid><originalsourceid>FETCH-LOGICAL-c614t-8b7b128086eba764b8cd5b811f56d36598033214296c2314ef8f394c1d1957823</originalsourceid><addsrcrecordid>eNptk11rFDEUhgdRbK1eeS8BQQTZmq-ZyfZCKHVtCy2CX7chMzmzm5KZrElmy_44_5tnu23tFslFwslz3nPyklMUrxk95EzWH3-dfbs8_F6LmoonxT5jtZpwKtXTB-e94kVKV5SWlaLsebHHy7qkpVD7xZ9Z10Gb3QoGSImYwZIcPETTOO_ymoSOJGjDYCfeDUByBJN7GDK5dnlBVs5bM_dumd1AVhDTmEjIC4gkROOJjeM8kS5EktdLIJxYZxrIkAjihqCWn1yH6C3WyCgx38QxnVw6az2QmUn5CLE0-ow6MfQ3t7PPpzOS8mjXL4tnnfEJXt3uB8XPL7MfJ2eTi6-n5yfHF5O2YjJPVFM3jCuqKmhMXclGtbZsFGNdWVlRlVNFhUAv-bRquWASOtWJqWyZZdOyVlwcFOdbXRvMlV5G15u41sE4fRMIca5NzK71oGkrKJV1IyUI2QhqKKUKqKkkL7GwRa1PW63l2PRgWzQTvdoR3b0Z3ELPw0pLIRW-AgXoXTMrWKI76VFHd9E29JrTitWY8v62Zgy_R0hZ9y614L0ZIIxJs6piU1UzIRB9-wi9CmMc0F3NORpUCcnpP2pu8M1u6AK22m5E9bGUU0ZVXW46PfwPhctC7_BTQecwvpPw7kHCAv9HXqTgx-zCkHbBD1uwjSGlCN29BYzqzVTozVTo7VQg_eah5ffs3RiIv-0zCDw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2229663420</pqid></control><display><type>article</type><title>Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>Taylor & Francis Open Access</source><creator>Saab, Charles ; Al-Saber, Feryal A ; Haddad, Jihad ; Jallo, Mahir Khalil ; Steitieh, Habib ; Bader, Giovanni ; Ibrahim, Mohamed</creator><creatorcontrib>Saab, Charles ; Al-Saber, Feryal A ; Haddad, Jihad ; Jallo, Mahir Khalil ; Steitieh, Habib ; Bader, Giovanni ; Ibrahim, Mohamed</creatorcontrib><description>Type 2 diabetes mellitus (T2DM) is a chronic progressive disease that requires treatment intensification with antihyperglycemic agents due to progressive deterioration of β-cell function. A large observational study of 45,868 patients with T2DM across 27 countries (EDGE) assessed the effectiveness and safety of vildagliptin as add-on to other oral antidiabetic drugs (OADs) versus other comparator OAD combinations. Here, we present results from the Middle East countries (Bahrain, Jordan, Kuwait, Lebanon, Oman, Palestine, and the United Arab Emirates).
Patients inadequately controlled with OAD monotherapy were eligible after the add-on treatment was chosen by the physician based on clinical judgment and patient need. Patients were assigned to either vildagliptin or comparator OADs (sulfonylureas, thiazolidinediones, glinides, α-glucosidase inhibitors, or metformin, except incretin-based therapies) based on the add-on therapy. The primary endpoint was the proportion of patients achieving a glycated hemoglobin (HbA1c) reduction of >0.3% without peripheral edema, hypoglycemia, discontinuation due to a gastrointestinal event, or weight gain≥5%. One of the secondary endpoints was the proportion of patients achieving HbA1c<7% without hypoglycemia or weight gain. Change in HbA1c from baseline to study endpoint and safety were also assessed.
Of the 4,780 patients enrolled in the Middle East, 2,513 received vildagliptin and 2,267 received other OADs. Overall, the mean (±standard deviation) age at baseline was 52.1±10.2 years, mean HbA1c was 8.5%±1.3%, and mean T2DM duration was 4.2±4.0 years. The proportion of patients achieving the primary (76.1% versus 61.6%, P<0.0001) and secondary (54.8% versus 29.9%, P<0.0001) endpoints was higher with vildagliptin than with the comparator OADs. The unadjusted odds ratios for the primary and secondary endpoints were 1.98 (95% confidence interval 1.75-2.25) and 2.8 (95% confidence interval 2.5-3.2), respectively, in favor of vildagliptin. Vildagliptin achieved a numerically greater reduction in HbA1c (1.7%) from baseline versus comparator OADs (1.4%). The overall incidence of adverse events was comparable between studied cohorts.
In real life, treatment with vildagliptin was associated with a higher proportion of patients with T2DM achieving better glycemic control without tolerability issues in the Middle East.</description><identifier>ISSN: 1178-2048</identifier><identifier>ISSN: 1176-6344</identifier><identifier>EISSN: 1178-2048</identifier><identifier>DOI: 10.2147/VHRM.S73703</identifier><identifier>PMID: 25750538</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Adamantane - administration & dosage ; Adamantane - adverse effects ; Adamantane - analogs & derivatives ; Adult ; Antidiabetics ; Biomarkers - blood ; Blood Glucose - drug effects ; Blood Glucose - metabolism ; Care and treatment ; Clinical medicine ; Clinical trials ; Developing countries ; Diabetes ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - diagnosis ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - epidemiology ; dipeptidyl peptidase-4 ; Dipeptidyl-Peptidase IV Inhibitors - administration & dosage ; Dipeptidyl-Peptidase IV Inhibitors - adverse effects ; Drug dosages ; Drug therapy ; Drug Therapy, Combination ; Endocrinology ; Female ; Glycated Hemoglobin A - metabolism ; Hospitals ; Humans ; Hypoglycemia ; Hypoglycemic agents ; Internal medicine ; LDCs ; Logistic Models ; Male ; Middle Aged ; Middle East ; Middle East - epidemiology ; Nitriles - administration & dosage ; Nitriles - adverse effects ; Odds Ratio ; oral antidiabetic drugs ; Original Research ; Patient outcomes ; Patients ; Peptides ; Prevalence ; Pyrrolidines - administration & dosage ; Pyrrolidines - adverse effects ; Ramadan ; real world ; Systematic review ; Time Factors ; Treatment Outcome ; Type 2 diabetes ; type 2 diabetes mellitus ; Vildagliptin</subject><ispartof>Vascular health and risk management, 2015-01, Vol.11 (default), p.149-155</ispartof><rights>COPYRIGHT 2015 Dove Medical Press Limited</rights><rights>2015. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2015 Saab et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c614t-8b7b128086eba764b8cd5b811f56d36598033214296c2314ef8f394c1d1957823</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2229663420/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2229663420?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25750538$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saab, Charles</creatorcontrib><creatorcontrib>Al-Saber, Feryal A</creatorcontrib><creatorcontrib>Haddad, Jihad</creatorcontrib><creatorcontrib>Jallo, Mahir Khalil</creatorcontrib><creatorcontrib>Steitieh, Habib</creatorcontrib><creatorcontrib>Bader, Giovanni</creatorcontrib><creatorcontrib>Ibrahim, Mohamed</creatorcontrib><title>Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study</title><title>Vascular health and risk management</title><addtitle>Vasc Health Risk Manag</addtitle><description>Type 2 diabetes mellitus (T2DM) is a chronic progressive disease that requires treatment intensification with antihyperglycemic agents due to progressive deterioration of β-cell function. A large observational study of 45,868 patients with T2DM across 27 countries (EDGE) assessed the effectiveness and safety of vildagliptin as add-on to other oral antidiabetic drugs (OADs) versus other comparator OAD combinations. Here, we present results from the Middle East countries (Bahrain, Jordan, Kuwait, Lebanon, Oman, Palestine, and the United Arab Emirates).
Patients inadequately controlled with OAD monotherapy were eligible after the add-on treatment was chosen by the physician based on clinical judgment and patient need. Patients were assigned to either vildagliptin or comparator OADs (sulfonylureas, thiazolidinediones, glinides, α-glucosidase inhibitors, or metformin, except incretin-based therapies) based on the add-on therapy. The primary endpoint was the proportion of patients achieving a glycated hemoglobin (HbA1c) reduction of >0.3% without peripheral edema, hypoglycemia, discontinuation due to a gastrointestinal event, or weight gain≥5%. One of the secondary endpoints was the proportion of patients achieving HbA1c<7% without hypoglycemia or weight gain. Change in HbA1c from baseline to study endpoint and safety were also assessed.
Of the 4,780 patients enrolled in the Middle East, 2,513 received vildagliptin and 2,267 received other OADs. Overall, the mean (±standard deviation) age at baseline was 52.1±10.2 years, mean HbA1c was 8.5%±1.3%, and mean T2DM duration was 4.2±4.0 years. The proportion of patients achieving the primary (76.1% versus 61.6%, P<0.0001) and secondary (54.8% versus 29.9%, P<0.0001) endpoints was higher with vildagliptin than with the comparator OADs. The unadjusted odds ratios for the primary and secondary endpoints were 1.98 (95% confidence interval 1.75-2.25) and 2.8 (95% confidence interval 2.5-3.2), respectively, in favor of vildagliptin. Vildagliptin achieved a numerically greater reduction in HbA1c (1.7%) from baseline versus comparator OADs (1.4%). The overall incidence of adverse events was comparable between studied cohorts.
In real life, treatment with vildagliptin was associated with a higher proportion of patients with T2DM achieving better glycemic control without tolerability issues in the Middle East.</description><subject>Adamantane - administration & dosage</subject><subject>Adamantane - adverse effects</subject><subject>Adamantane - analogs & derivatives</subject><subject>Adult</subject><subject>Antidiabetics</subject><subject>Biomarkers - blood</subject><subject>Blood Glucose - drug effects</subject><subject>Blood Glucose - metabolism</subject><subject>Care and treatment</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Developing countries</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - diagnosis</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - epidemiology</subject><subject>dipeptidyl peptidase-4</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - administration & dosage</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - adverse effects</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Endocrinology</subject><subject>Female</subject><subject>Glycated Hemoglobin A - metabolism</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Hypoglycemia</subject><subject>Hypoglycemic agents</subject><subject>Internal medicine</subject><subject>LDCs</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Middle East</subject><subject>Middle East - epidemiology</subject><subject>Nitriles - administration & dosage</subject><subject>Nitriles - adverse effects</subject><subject>Odds Ratio</subject><subject>oral antidiabetic drugs</subject><subject>Original Research</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Peptides</subject><subject>Prevalence</subject><subject>Pyrrolidines - administration & dosage</subject><subject>Pyrrolidines - adverse effects</subject><subject>Ramadan</subject><subject>real world</subject><subject>Systematic review</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Type 2 diabetes</subject><subject>type 2 diabetes mellitus</subject><subject>Vildagliptin</subject><issn>1178-2048</issn><issn>1176-6344</issn><issn>1178-2048</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptk11rFDEUhgdRbK1eeS8BQQTZmq-ZyfZCKHVtCy2CX7chMzmzm5KZrElmy_44_5tnu23tFslFwslz3nPyklMUrxk95EzWH3-dfbs8_F6LmoonxT5jtZpwKtXTB-e94kVKV5SWlaLsebHHy7qkpVD7xZ9Z10Gb3QoGSImYwZIcPETTOO_ymoSOJGjDYCfeDUByBJN7GDK5dnlBVs5bM_dumd1AVhDTmEjIC4gkROOJjeM8kS5EktdLIJxYZxrIkAjihqCWn1yH6C3WyCgx38QxnVw6az2QmUn5CLE0-ow6MfQ3t7PPpzOS8mjXL4tnnfEJXt3uB8XPL7MfJ2eTi6-n5yfHF5O2YjJPVFM3jCuqKmhMXclGtbZsFGNdWVlRlVNFhUAv-bRquWASOtWJqWyZZdOyVlwcFOdbXRvMlV5G15u41sE4fRMIca5NzK71oGkrKJV1IyUI2QhqKKUKqKkkL7GwRa1PW63l2PRgWzQTvdoR3b0Z3ELPw0pLIRW-AgXoXTMrWKI76VFHd9E29JrTitWY8v62Zgy_R0hZ9y614L0ZIIxJs6piU1UzIRB9-wi9CmMc0F3NORpUCcnpP2pu8M1u6AK22m5E9bGUU0ZVXW46PfwPhctC7_BTQecwvpPw7kHCAv9HXqTgx-zCkHbBD1uwjSGlCN29BYzqzVTozVTo7VQg_eah5ffs3RiIv-0zCDw</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Saab, Charles</creator><creator>Al-Saber, Feryal A</creator><creator>Haddad, Jihad</creator><creator>Jallo, Mahir Khalil</creator><creator>Steitieh, Habib</creator><creator>Bader, Giovanni</creator><creator>Ibrahim, Mohamed</creator><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove Press</general><general>Dove Medical Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20150101</creationdate><title>Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study</title><author>Saab, Charles ; Al-Saber, Feryal A ; Haddad, Jihad ; Jallo, Mahir Khalil ; Steitieh, Habib ; Bader, Giovanni ; Ibrahim, Mohamed</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c614t-8b7b128086eba764b8cd5b811f56d36598033214296c2314ef8f394c1d1957823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adamantane - administration & dosage</topic><topic>Adamantane - adverse effects</topic><topic>Adamantane - analogs & derivatives</topic><topic>Adult</topic><topic>Antidiabetics</topic><topic>Biomarkers - blood</topic><topic>Blood Glucose - drug effects</topic><topic>Blood Glucose - metabolism</topic><topic>Care and treatment</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Developing countries</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - diagnosis</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - epidemiology</topic><topic>dipeptidyl peptidase-4</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - administration & dosage</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - adverse effects</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Endocrinology</topic><topic>Female</topic><topic>Glycated Hemoglobin A - metabolism</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Hypoglycemia</topic><topic>Hypoglycemic agents</topic><topic>Internal medicine</topic><topic>LDCs</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Middle East</topic><topic>Middle East - epidemiology</topic><topic>Nitriles - administration & dosage</topic><topic>Nitriles - adverse effects</topic><topic>Odds Ratio</topic><topic>oral antidiabetic drugs</topic><topic>Original Research</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Peptides</topic><topic>Prevalence</topic><topic>Pyrrolidines - administration & dosage</topic><topic>Pyrrolidines - adverse effects</topic><topic>Ramadan</topic><topic>real world</topic><topic>Systematic review</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Type 2 diabetes</topic><topic>type 2 diabetes mellitus</topic><topic>Vildagliptin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saab, Charles</creatorcontrib><creatorcontrib>Al-Saber, Feryal A</creatorcontrib><creatorcontrib>Haddad, Jihad</creatorcontrib><creatorcontrib>Jallo, Mahir Khalil</creatorcontrib><creatorcontrib>Steitieh, Habib</creatorcontrib><creatorcontrib>Bader, Giovanni</creatorcontrib><creatorcontrib>Ibrahim, Mohamed</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Health Management Database (Proquest)</collection><collection>ProQuest_Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Vascular health and risk management</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saab, Charles</au><au>Al-Saber, Feryal A</au><au>Haddad, Jihad</au><au>Jallo, Mahir Khalil</au><au>Steitieh, Habib</au><au>Bader, Giovanni</au><au>Ibrahim, Mohamed</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study</atitle><jtitle>Vascular health and risk management</jtitle><addtitle>Vasc Health Risk Manag</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>11</volume><issue>default</issue><spage>149</spage><epage>155</epage><pages>149-155</pages><issn>1178-2048</issn><issn>1176-6344</issn><eissn>1178-2048</eissn><abstract>Type 2 diabetes mellitus (T2DM) is a chronic progressive disease that requires treatment intensification with antihyperglycemic agents due to progressive deterioration of β-cell function. A large observational study of 45,868 patients with T2DM across 27 countries (EDGE) assessed the effectiveness and safety of vildagliptin as add-on to other oral antidiabetic drugs (OADs) versus other comparator OAD combinations. Here, we present results from the Middle East countries (Bahrain, Jordan, Kuwait, Lebanon, Oman, Palestine, and the United Arab Emirates).
Patients inadequately controlled with OAD monotherapy were eligible after the add-on treatment was chosen by the physician based on clinical judgment and patient need. Patients were assigned to either vildagliptin or comparator OADs (sulfonylureas, thiazolidinediones, glinides, α-glucosidase inhibitors, or metformin, except incretin-based therapies) based on the add-on therapy. The primary endpoint was the proportion of patients achieving a glycated hemoglobin (HbA1c) reduction of >0.3% without peripheral edema, hypoglycemia, discontinuation due to a gastrointestinal event, or weight gain≥5%. One of the secondary endpoints was the proportion of patients achieving HbA1c<7% without hypoglycemia or weight gain. Change in HbA1c from baseline to study endpoint and safety were also assessed.
Of the 4,780 patients enrolled in the Middle East, 2,513 received vildagliptin and 2,267 received other OADs. Overall, the mean (±standard deviation) age at baseline was 52.1±10.2 years, mean HbA1c was 8.5%±1.3%, and mean T2DM duration was 4.2±4.0 years. The proportion of patients achieving the primary (76.1% versus 61.6%, P<0.0001) and secondary (54.8% versus 29.9%, P<0.0001) endpoints was higher with vildagliptin than with the comparator OADs. The unadjusted odds ratios for the primary and secondary endpoints were 1.98 (95% confidence interval 1.75-2.25) and 2.8 (95% confidence interval 2.5-3.2), respectively, in favor of vildagliptin. Vildagliptin achieved a numerically greater reduction in HbA1c (1.7%) from baseline versus comparator OADs (1.4%). The overall incidence of adverse events was comparable between studied cohorts.
In real life, treatment with vildagliptin was associated with a higher proportion of patients with T2DM achieving better glycemic control without tolerability issues in the Middle East.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>25750538</pmid><doi>10.2147/VHRM.S73703</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1178-2048 |
| ispartof | Vascular health and risk management, 2015-01, Vol.11 (default), p.149-155 |
| issn | 1178-2048 1176-6344 1178-2048 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_0c30047b44e34b30a0008e0a64254b8d |
| source | Open Access: PubMed Central; Publicly Available Content Database (Proquest) (PQ_SDU_P3); Taylor & Francis Open Access |
| subjects | Adamantane - administration & dosage Adamantane - adverse effects Adamantane - analogs & derivatives Adult Antidiabetics Biomarkers - blood Blood Glucose - drug effects Blood Glucose - metabolism Care and treatment Clinical medicine Clinical trials Developing countries Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - epidemiology dipeptidyl peptidase-4 Dipeptidyl-Peptidase IV Inhibitors - administration & dosage Dipeptidyl-Peptidase IV Inhibitors - adverse effects Drug dosages Drug therapy Drug Therapy, Combination Endocrinology Female Glycated Hemoglobin A - metabolism Hospitals Humans Hypoglycemia Hypoglycemic agents Internal medicine LDCs Logistic Models Male Middle Aged Middle East Middle East - epidemiology Nitriles - administration & dosage Nitriles - adverse effects Odds Ratio oral antidiabetic drugs Original Research Patient outcomes Patients Peptides Prevalence Pyrrolidines - administration & dosage Pyrrolidines - adverse effects Ramadan real world Systematic review Time Factors Treatment Outcome Type 2 diabetes type 2 diabetes mellitus Vildagliptin |
| title | Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T12%3A22%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20and%20tolerability%20of%20second-line%20treatment%20with%20vildagliptin%20versus%20other%20oral%20drugs%20for%20type%202%20diabetes%20in%20a%20real-world%20setting%20in%20the%20Middle%20East:%20results%20from%20the%20EDGE%20study&rft.jtitle=Vascular%20health%20and%20risk%20management&rft.au=Saab,%20Charles&rft.date=2015-01-01&rft.volume=11&rft.issue=default&rft.spage=149&rft.epage=155&rft.pages=149-155&rft.issn=1178-2048&rft.eissn=1178-2048&rft_id=info:doi/10.2147/VHRM.S73703&rft_dat=%3Cgale_doaj_%3EA449108758%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c614t-8b7b128086eba764b8cd5b811f56d36598033214296c2314ef8f394c1d1957823%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2229663420&rft_id=info:pmid/25750538&rft_galeid=A449108758&rfr_iscdi=true |